ASH

• ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) CEO Dr. Laurence Cooper believes that the company’s cell programming languages set it apart from other cancer researchers. • The company’s Sleeping Beauty platform allows for T cell modification without the use of a viral...

Thomas Yip of FBR commented in a note on Monday that shares of Geron Corporation (NASDAQ: GERN) are undervalued. Geron's imetelstat's pilot study will be presented during the upcoming American Society of Hematology (ASH) meeting in early December. Yip stated the presentation could "attract...